At last check, call volume on the SPDR S&P Biotech ETF (XBI) was running at an accelerated clip, with 16,000 contracts traded so far. Buy-to-open activity has been detected at the weekly 5/11 91-strike call. 97.87 -- and it is one of the best ETFs to own in May. The iShares Nasdaq Biotechnology ETF (IBB) has seen in influx of call and put trading today, with about 6,800 of the former and 8,000 of the latter exchanged -- two times what's typically seen at this point in the day. Bulls appear to be purchasing new positions at the May 106 call, while bears seem to be buying to open weekly 5/11 105-strike puts, betting on a reversal lower by tonight's close.

And when I say the markdowns on these funds are ridiculous, I mean it. These 5 CEFs are “hardwired” to deliver a 28% average total return in the next 12 months as these massive discounts return to normal. In fact, the gap has already started to close, so you need to make your move now! Click here and I’ll give you the names, ticker symbols, buy-under prices and my complete research on all 5 of these proven wealth generators so you can grab an early stake and kick-start your 8.2% income stream today.

108 a share, the IBB has holdings in Biogene, Celgene, Amgen, Gilead Sciences, lliumina, Incyte Corporation and Alexion Pharmaceuticals. XBI provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. 85, it has holdings in Array BioPharm, Amicus Therapeutics, and Neurocrine Biotsciences.and Exelixis. The investment seeks daily investment results that correspond to two times (2x) the daily performance of the NASDAQ Biotechnology Index. 57.50, it has holdings in Biogen, Amgen, and Gilead Sciences.

Ever since the first Baby Boomer retired in 2008, biotech and pharmaceutical names have been some of the most explosive. And we certainly can’t ignore the catalysts likely to send such investments higher. For the next 20 years, 10,000 Boomers will retire by the day, seeking better care, new innovation and ways to live longer. While it’s showing signs of pulling back, this is a long-term hold.

We recommended PLOW just the other day on the snow. 36.62 and is falling apart. 52.86 and remains on hold. 70, which would refill its bearish gap. 36.60 and remains a long-term hold. This trade remains a long-term hold on the electric vehicle (EV) boom. 57.30. Both positions remain on hold. This remains a hedge against the long positions.

As of the latest prospectus, the trust held about 26.8 million ounces of gold. The other two funds have similar statements in their prospectuses. The only major difference between the three funds is the cost involved. And although the difference between iShares' low 0.25% expense ratio and the SPDR fund's 0.40% may sound quite small, it can add up significantly over time.

10,000 and the price of gold increases at an average rate of 5% per year over the next 30 years. As you can see in the chart, the annualized returns of these three ETFs differ almost exactly in proportion to the differences in the expense ratios, as would be expected among ETFs with identical investment portfolios.

Which is the best gold ETF for you, Because of the fee difference, I'd suggest the iShares Gold Trust for investors who want to add some exposure to the precious metal to their investment portfolio. To be clear, all three funds are likely to be cheaper than owning physical gold bullion.

Paying to insure and store gold can easily surpass the 0.40% of your assets each year that the most expensive of the three charges, and that doesn't even take the purchase premium into account. Having said that, lower fees are almost always better when you're talking about the exact same investment portfolio. If I were to add gold to my portfolio today, the iShares Gold Trust would be my top choice.

The Vanguard International High Dividend Yield ETF (NASDAQ:VYMI) is the international counterpart to the popular Vanguard High Dividend Yield ETF (NYSEARCA:VYM). This Vanguard ETF is ideal for income-seeking investors looking for ex-U.S. That’s right, VYMI allocates 21.40% of its weight to emerging markets companies, so it can be used in unison with a fund like VEA. The combination of developed and developing markets exposure makes VYMI look tantalizingly inexpensive on valuation.